Neisi Dajomes, a renowned Ecuadorian weightlifter, has accepted a 14-month suspension imposed by the International Testing Agency (ITA) due to a positive test for clomifene, which was detected during a doping control in April 2025. In her statement, Dajomes clarified that the clomifene found in her system was a result of legitimate medical treatment for polycystic ovary syndrome (PCOS), which she underwent to stimulate ovulation. This context highlights the complexities of doping regulations in sports, especially when legitimate medical treatments are involved.

Dajomes conceded that she made an administrative error by not securing the Therapeutic Use Exemption (TUE) prior to starting her treatment. She acknowledged her commitment to reproductive health but admitted that this oversight led to the unfortunate doping violation. Dajomes stated that her intention was never to enhance her athletic performance through prohibited substances, emphasizing the importance of following proper procedures in medical treatment to avoid regulatory issues.

The situation sheds light on the broader implications of anti-doping policies, particularly how athletes must navigate health concerns while also adhering to strict regulations. Dajomes’ case may prompt discussions within the sports community about the need for clarity and support regarding medical exemptions and the potential consequences of oversight in managing health while competing at high levels.